chlorophyll-a has been researched along with 4-hydroxymephenytoin* in 1 studies
1 other study(ies) available for chlorophyll-a and 4-hydroxymephenytoin
| Article | Year |
|---|---|
Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19.
Multiple studies suggest that phenytoin concentrations increase with CBZ co-medication. This study evaluated the hypothesis that CBZ and/or its major metabolite (CBZE) inhibit CYP2C19-mediated phenytoin metabolism using human liver microsomes and cDNA-expressed CYP2C19. Oxcarbazepine (OXC), and its 10-monohydroxy metabolite (MHD) were also evaluated. CBZ and MHD inhibited CYP2C19-mediated phenytoin metabolism at therapeutic concentrations. Thus, administration of CBZ and OXC with CYP2C19 substrates with narrow therapeutic ranges should be done cautiously. Topics: Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Carbamazepine; Chlorophyll; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; In Vitro Techniques; Liver; Mephenytoin; Microsomes; Mixed Function Oxygenases; Oxcarbazepine; Phenytoin; Recombinant Proteins | 2002 |